Adjuvant treatment with vindesine for metastatic melanoma: in response to the study of Eigentler et al. (2008).

The study of adjuvant vindesine for clinically apparent, resectable metastases from melanoma, reported by Eigentler et al. [1] in the October 2008 issue of the journal, shows a discernible overall survival advantage, in favour of adjuvant vindesine versus observation. This survival advantage, as reported by Eigentler, is short of statistical significance (P=0.07). On the strength of this P value, the authors referring to our study [2] conclude that their randomized trial did not confirm earlier reports of beneficial effect of adjuvant vindesine and therefore cannot be recommended [1].